Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:03:32.656Z.
Calculation as of: 2026-10-06T17:03:32.656Z.
Quote observation: 2026-10-06T17:00:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869efbf6e11e98c8b36b953a9b631e7639c239a9e2012f11ad9cca4b0e6b7a7d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$663.65M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$668.57M
EV/EBIT Ratio
61.05x
TTM Avg
21.67x
3Y Avg
25.85x
5Y Avg
35.25x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OmniAb, Inc. (OABI) | $648.75M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $632.00M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $663.65M | N/A | N/A | N/A | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $631.73M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $629.56M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.57M | 61.05x | 21.67x | 25.85x | 35.25x |
| Prime Medicine, Inc. (PRME)vs › | $628.39M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $671.91M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $674.21M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
